Ubrogepant

Brand names: Ubrelvy · Active ingredient: Ubrogepant

In short: UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine.

Forms & strengthsUBRELVY 50 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with “U50” on one side. UBRELVY 100 mg is supplied as white to off-white, capsule-shaped, biconvex tablets debossed with “U100” on one side.
LabelSportpharm LLC
Label updatedOct 01, 2026

What is Ubrogepant used for?

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

UBRELVY is not indicated for the preventive treatment of migraine.

Ubrogepant dosage

The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.

If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

Dosing modifications for concomitant use of specific drugs and for patients with hepatic or renal impairment are provided in Table 1.

Dosage Modifications | Initi

a

l Dose | Second Dose

a

(if needed)

Concomitant Drug

Moderate CYP3A4 Inhibitors

(

7.1

) | 50 mg | Avoid within 24 hours

Weak CYP3A4 Inhibitors

(

7.1

) | 50 mg | 50 mg

Strong CYP3A4 Inducers

(

7.2

) | Avoid concomitant use

Weak & Moderate CYP3A4 Inducers

(

7.2

) | 100 mg | 100 mg

BCRP and/or P-gp only Inhibitors

(

7.3

) | 50 mg | 50 mg

Spec

i

fic

Populations

Severe Hepatic Impairment (Child-Pugh Class C)

(

8.6

) | 50 mg | 50 mg

Severe Renal Impairment (CLcr 15-29 mL/min)

(

8.7

) | 50 mg | 50 mg

End-Stage Renal Disease (CLcr <15 mL/min)

(

8.7

) | Avoid use

a Second dose may be taken at least 2 hours after the initial dose

How to take Ubrogepant — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Patient Information).

Hypersensitivity Reactions

Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur with UBRELVY. Advise patients to discontinue UBRELVY and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions

.

Hypertension

Inform patients that hypertension can develop or pre-existing hypertension can worsen with UBRELVY, and that they should contact their healthcare providers if they experience elevation in their blood pressure

.

Raynaud’s Phenomenon

Inform patients that Raynaud’s phenomenon can develop or worsen with UBRELVY. Advise patients to discontinue UBRELVY and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon

.

Drug Interactions

Inform patients that UBRELVY may interact with certain other drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription medications, over-the-counter medications, or herbal products

[see Contraindication

s

(

4

) and Drug Interactions (

7.1

,

7.2

,

7.3

)]. …

Warnings & precautions

Do not take this medicine if: UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors

In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema

Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported with use of UBRELVY. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions occurred within hours after dosing and were not serious, and some reactions led to discontinuation. If a serious or severe hypersensitivity reaction occurs, discontinue UBRELVY and institute appropriate therapy

.

Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including UBRELVY, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with UBRELVY for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of UBRELVY is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including UBRELVY. …

Ubrogepant side effects

The following clinically significant adverse reactions are described elsewhere in labeling:

Hypersensitivity Reactions

Hypertension

Raynaud’s Phenomenon

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of UBRELVY was evaluated in 3,624 subjects who received at least one dose of UBRELVY. In two randomized, double-blind, placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 1,439 patients received UBRELVY 50 mg or 100 mg

. Of the UBRELVY-treated patients in these 2 studies, approximately 89% were female, 82% were White, 15% were Black, and 17% were of Hispanic or Latino ethnicity. The mean age at study entry was 41 years (range of 18-75 years).

Long-term safety was assessed in 813 patients, dosing intermittently for up to 1 year in an open-label extension study. Patients were permitted to treat up to 8 migraines per month with UBRELVY. Of these 813 patients, 421 patients were exposed to 50 mg or 100 mg for at least 6 months, and 364 patients were exposed to these doses for at least one year, all of whom treated at least two migraine attacks per month, on average. In that study, 2.5% of patients were withdrawn from UBRELVY because of an adverse reaction. …

Drug interactions

Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of ubrogepant

. UBRELVY should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)

.

Co-administration of UBRELVY with verapamil, a moderate CYP3A4 inhibitor, resulted in an increase in ubrogepant exposure

. Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice)

.

No dedicated drug interaction study was conducted with ubrogepant and weak CYP3A4 inhibitors. Dose adjustment is recommended with concomitant use of UBRELVY with weak CYP3A4 inhibitors

.

Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a significant reduction in ubrogepant exposure

[

s

ee

Clinical Pharmacology

(

12.3

)

]. In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort), loss of ubrogepant efficacy is expected, and concomitant use should be avoided.

Co-administration of UBRELVY with moderate or weak CYP3A4 inducers was not evaluated in a clinical study. Dose adjustment is recommended with concomitant use of UBRELVY and moderate or weak CYP3A4 inducers

. …

About this medicine

The active ingredient of UBRELVY is ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The chemical name of ubrogepant is (3'

S)-

N-((3

S,5

S,6

R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[

b]pyridine-6,3'-pyrrolo[2,3-

b]pyridine]-3-carboxamide and has the following structural formula:

The molecular formula is C

29H

26F

3N

5O

3and molecular weight is 549.6. Ubrogepant is a white to off-white powder. It is freely soluble in ethanol, methanol, acetone, and acetonitrile; and is practically insoluble in water.

UBRELVY is available as tablets for oral administration containing 50 mg or 100 mg ubrogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.

How it works: Ubrogepant is a calcitonin gene-related peptide receptor antagonist. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 36106b14-d410-4faf-a361-2871de8198c3. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine